BMS-564929 Reference

Plain English

What it is

BMS-564929 is a SARM, short for selective androgen receptor modulator, which means a lab-made drug built to switch on the body's muscle-building hormone signals while trying to leave other tissues alone. A drug company, Bristol-Myers Squibb, created it, but today it is sold only as a research chemical and is not an approved medicine.

What people use it for

In the bodybuilding and physique community, people talk about using it to add muscle and get leaner. That use is based on personal stories, not on any approval, and the community is mostly guessing from a very small amount of published data.

What the science shows

Most of what is known comes from early animal work, where the compound favored building muscle over acting on the prostate in rats. An early-stage trial in healthy men did exist, but the drug company never moved it forward, so human evidence is thin and its current status is unknown.

The catch

SARMs are not approved by the FDA for human use, and regulators take enforcement action against sellers who market them illegally, often mislabeled. Sport's anti-doping rules (WADA) ban all SARMs at all times as anabolic agents under category S1.2. The class carries real risks reported in studies and case reports, including lowered natural testosterone, liver strain, and heart and blood-vessel effects such as a raised risk of heart attack and stroke.

Reference summary

Phase 1 healthy-men trial existed; no later development. Tissue-selectivity profile was studied in early development.

Regulatory and posture

Categories

SARM

Aliases

Non-steroidal SARM, Bristol-Myers Squibb investigational

Evidence posture

preclinical - FDA enforcement attention. Sold only as a research chemical, not for human consumption per legal seller terms. WADA-prohibited under category S1.2 at all times. Did not advance past early development by the original sponsor; community use extrapolates from minimal published data.

Regulatory status

No FDA-approved BMS-564929 drug label. WADA prohibits SARMs under category S1.2 at all times. FDA enforcement against SARMs sellers applies. BMS-564929 was an early Bristol-Myers Squibb SARM investigational candidate that did not advance.

Content review status

research reference